DexCom/$DXCM
DexCom stock rises after Q2 EPS of $0.70 beat $0.61 estimate, signaling stronger-than-expected growth.
16 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About DexCom
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
Ticker
$DXCM
Sector
Primary listing
Employees
11,050
Headquarters
Website
DexCom Metrics
BasicAdvanced
$31bn
32.90
$2.54
1.45
-
Price and volume
Market cap
$31bn
Beta
1.45
52-week high
$84.70
52-week low
$54.11
Average daily volume
5m
Financial strength
Current ratio
1.733
Quick ratio
1.359
Long term debt to equity
50.561
Total debt to equity
51.35
Interest coverage (TTM)
75.94%
Profitability
EBITDA (TTM)
1,403.2
Gross margin (TTM)
62.47%
Net profit margin (TTM)
20.12%
Operating margin (TTM)
22.92%
Effective tax rate (TTM)
21.90%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
10.33%
Return on equity (TTM)
38.49%
Valuation
Price to earnings (TTM)
32.902
Price to revenue (TTM)
6.486
Price to book
12.01
Price to tangible book (TTM)
12.62
Price to free cash flow (TTM)
22.941
Free cash flow yield (TTM)
4.36%
Free cash flow per share (TTM)
3.638
Growth
Revenue change (TTM)
15.54%
Earnings per share change (TTM)
77.35%
3-year revenue growth (CAGR)
15.83%
10-year revenue growth (CAGR)
26.08%
3-year earnings per share growth (CAGR)
43.16%
10-year earnings per share growth (CAGR)
26.25%
What the Analysts think about DexCom
Analyst ratings (Buy, Hold, Sell) for DexCom stock.
DexCom Financial Performance
Revenues and expenses
DexCom Earnings Performance
Company profitability
DexCom News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.